To understand how MYC might alter response to immune checkpoint inhibitors, we initiated our studies using a genetically engineered mouse model of triple negative breast cancer (MTB/TOM)26, where MYC expression in breast epithelial cells can be switched on and off with doxycycline. This evidence concerns the gene MYC and triple-negative breast carcinoma.